Aplastic Anemia Risk Markers
Links shared publicly online about this topic
Researchers Identify Markers for Aplastic Anemia Risk
health.msn.com — “Researchers Identify Markers for Aplastic Anemia Risk” View full resource at health.msn.com
Most Recently Shared on September 21, 2010 at 8:34 pm By:
Researchers Identify Markers for Aplastic Anemia Risk: http://on.msn.com/aDogPd
Researchers Identify Markers for Aplastic Anemia Risk - Drugs.com MedNews
drugs.com — “Biomarkers associated with increased risk of relapse and death among patients with severe aplastic anemia have been identified by U.S. researchers. Aplastic ane” View full resource at drugs.com
Most Recently Shared on September 21, 2010 at 9:15 pm By:
Drugs and Devices OW OW Health
Researchers Identify Markers for Aplastic Anemia Risk: TUESDAY, Sept. 21 -- Biomarkers associated with increa... http://bit.ly/aZOq9K #drug
Shorter biological marker length in aplastic anemia patients linked to higher relapse, death rates
physorg.com — “Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of ...” View full resource at physorg.com
Most Recently Shared on September 21, 2010 at 8:36 pm By:
PhysOrg Health News Health News
Shorter biological marker length in aplastic anemia patients linked to higher relapse, death rates http://tw.physorg.com/204305766
Medical News: First Response to ESAs Marker for Outcome in CKD - in Nephrology, General Nephrology from MedPage Today
medpagetoday.com — “A poor initial response to darbepoetin alfa (Aranesp) appears to increase risk of cardiovascular events and death in nondialysis chronic kidney disease, type 2 diabetes, and anemia, researchers found.” View full resource at medpagetoday.com
Most Recently Shared on September 16, 2010 at 3:27 pm By:
First Response to ESAs Marker for Outcome in CKD (CME/CE) http://ow.ly/1928yK
First Response to ESAs Marker for Outcome in CKD (CME/CE) - QualityPoint Technologies
qualitypointtech.net — “(MedPage Today) -- A poor initial response to darbepoetin alfa (Aranesp) appears to increase risk of cardiovascular events and death in non-dialysis chronic kidney disease, type 2 diabetes, and anemia, researchers found.” View full resource at qualitypointtech.net
Most Recently Shared on September 16, 2010 at 2:37 pm By:
First Response to ESAs Marker for Outcome in CKD (CME/CE): (MedPage Today) -- A poor initial response to darbepoet... http://bit.ly/cWK3YN
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
msn
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
-
PhysOrg Health News
PhysOrg.com Health and Medicine News Stories
Advertisement
